In vivo engineering of CAR-T cells: delivery strategies and clinical translation
Tongji Hospital · Huazhong University of Science and Technology · +1 more institution
Abstract
Chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment landscape for hematologic malignancies. Nonetheless, its broad clinical adoption is constrained by the logistical, financial, and safety burdens associated with ex vivo cell manufacturing. In vivo CAR-T engineering has emerged as a transformative alternative, enabling the direct reprogramming of endogenous T cells through systemic delivery of CAR-encoding constructs via viral or non-viral vectors. This strategy eliminates the need for leukapheresis, genetic modification, and reinfusion, paving the way for simplified, scalable, and potentially “off-the-shelf” immunotherapies. While challenges such as cytokine release syndrome (CRS) and…
Citation impact
- FWCI
- 66.93
- Percentile
- 100%
- References
- 191
Authors
5- YGYang Gao
Tongji Hospital, Huazhong University of Science and Technology
- JHJianlin Hu
Tongji Hospital, Huazhong University of Science and Technology
- NANing An
Tongji Hospital, Huazhong University of Science and Technology
- XWXinyu Wen
Tongji Hospital, Huazhong University of Science and Technology
- CLChunrui LiCorresponding
Tongji Hospital, Huazhong University of Science and Technology, Hubei University
Topics & keywords
- Immunotherapy
- Reprogramming
- In vivo
- Chimeric antigen receptor
- Immunogenicity
- Immune system
- Cytokine release syndrome
- Ex vivo
- Industry, innovation and infrastructure